Table 1

OB-202/DM-230 and CONQUER baseline demographics and clinical characteristics (randomized type 2 diabetes population)

OB-202/DM-230CONQUER type 2 diabetes population
Placebo
(n = 55)PHEN/TPM 
ER 15/92
(n = 75)Placebo
(n = 157)PHEN/TPM 
ER 7.5/46
(n = 67)PHEN/TPM ER 15/92
(n = 164)
Mean age, years (SD)49.5 (8.6)49.7 (7.5)52.6 (9.8)52.5 (9.3)52.1 (10.1)
Female sex, n (%)32 (58)58 (77)112 (71)44 (66)102 (62)
Race, n (%)
 Caucasian46 (84)66 (88)133 (85)63 (94)136 (83)
 African American7 (13)8 (11)19 (12)3 (5)23 (14)
 Asian1 (2)1 (1)3 (2)03 (2)
 Other*1 (2)03 (2)1 (2)5 (3)
Ethnicity, n (%)
 Hispanic or Latino30 (55)47 (63)46 (29)21 (31)50 (31)
Mean weight, kg (SD)98.1 (17.0)94.9 (17.9)99.3 (18.6)97.2 (16.1)103.2 (20.1)
Mean BMI, kg/m2 (SD)35.2 (5.0)35.5 (4.7)36.2 (5.2)35.3 (4.3)37.1 (5.2)
Mean waist circumference, cm (SD)111.0 (11.6)109.0 (11.7)112.7 (12.5)111.4 (10.8)114.1 (12.8)
HbA1c, % (SD) [mmol/mol (SD)]8.5 (1.3) 
[69 (14.2)]8.8 (1.2) 
[73 (13.1)]6.9 (1.3) 
[52 (14.2)]6.8 (1.2) 
[51 (13.1)]6.8 (1.1) 
[51 (12.0)]
Type 2 diabetes duration
 Mean years with diagnosis (SD)8.0 (6.6)9.0 (7.7)5.0 (3.9)5.1 (4.3)4.6 (3.6)
 ≥5 years since diagnosis, n (%)29 (53)49 (65)66 (42)27 (40)61 (37)
Antidiabetic medication use
 Mean number of medications per subject (SD)1.6 (0.9)1.6 (0.9)0.6 (0.5)0.6 (0.5)0.6 (0.5)
 1 oral medication, n (%)16 (29)21 (28)91 (58)40 (60)95 (58)
 2 oral medications, n (%)26 (47)37 (49)1 (1)1 (1)2 (1)
 ≥3 oral medications, n (%)7 (13)9 (12)0 (0)0 (0)0 (0)
Diagnosed with dyslipidemia,† n (%)30 (55)39 (52)50 (32)27 (40)52 (32)
Diagnosed with hypertension, n (%)23 (42)35 (47)82 (52)40 (60)91 (55)
Number of metabolic risk factors, n (%)
 ≥352 (95)69 (92)143 (91)60 (90)144 (88)
 ≥439 (71)55 (73)105 (67)53 (79)120 (73)
 522 (40)34 (45)63 (40)32 (48)74 (45)
  • *Other includes American Indian, Alaskan Native, Native Hawaiian, or other Pacific Islander. †Dyslipidemia was defined as triglycerides ≥200 and ≤400 mg/dL or requirement for two or more medications to achieve control, defined as <200 mg/dL.

  • ‡Metabolic risk factors included elevated fasting glucose levels, elevated waist circumference, elevated triglyceride levels, reduced HDL cholesterol level, and elevated blood pressure, per the criteria for metabolic syndrome outlined by Alberti et al. (28).